Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

Published:2023-12 Issue:6 Volume:89 Page:1149-1158
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Papp Kim A.,Blauvelt Andrew,Puig Lluís,Ohtsuki Mamitaro,Beissert Stefan,Gooderham Melinda,Amin Ahmad Z.,Liu Jie,Wu Tianshuang,Azam Tofial,Stakias Vassilis,Espaillat Ramon,Sinvhal Ranjeeta,Soliman Ahmed M.,Pang Yinuo,Chen Michael M.,Lebwohl Mark G.

Funder

AbbVie Canada

AbbVie

Publisher

Elsevier BV

Subject

Dermatology

Reference27 articles.

1. Pathogenesis and clinical features of psoriasis;Griffiths;Lancet,2007

2. The psychosocial burden of psoriasis;Kimball;Am J Clin Dermatol,2005

3. Biologic fatigue in psoriasis;Levin;J Dermatolog Treat,2014

4. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis;Hawkes;J Immunol,2018

5. Prescribing information,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risankizumab: Mechanism of action, clinical and translational science;Clinical and Translational Science;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP